klinični primer
Alja Drobnič (Author), Marko Boc (Author), Neva Volk (Author)

Abstract

Rak debelega črevesa in danke je med najpogostejšimi raki. Ob postavitvi diagnoze ima 23 % bolnikov razsejano obliko bolezni, 5-letno čisto preživetje bolnikov z razsejano boleznijo je 9 %. Z imunoterapijo lahko pri tumorjih z mutacijami v MMR (mismatch repair) genih oziroma visoko mikrosatelitno nestabilnostjo (MSI-H) dosežemo dolgotrajen odgovor na zdravljenje. V nadaljevanju je predstavljen primer bolnika na zdravljenju s pembrolizumabom, pri katerem smo dosegli regres bolezni.

Keywords

rak rektuma;sistemsko zdravljenje;rak prebavil;

Data

Language: Slovenian
Year of publishing:
Typology: 1.08 - Published Scientific Conference Contribution
Organization: OI - Institute of Oncology
Publisher: Onkolološki inštitut
UDC: 616.3
COBISS: 135648003 Link will open in a new window
Parent publication: Tumorji prebavil
Views: 15
Downloads: 4
Average score: 0 (0 votes)
Metadata: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Other data

Secondary language: English
Secondary title: Treatment of disseminated rectal carcinoma with immunotherapy
Secondary abstract: Colorectal cancer is among the most common cancers. At diagnosis, 23% of patients have disseminated form of the disease, the 5-year net survival of patients with disseminated disease is 9%. With immunotherapy in tumors with mutations in MMR (mismatch repair) genes or high microsatellites instability (MSI-H), we can achieve a long-term response to treatment. We present a case report of a patient treated with pembrolizumab, in whom we achieved disease regression.
Source comment: Nasl. z nasl. zaslona; Opis vira z dne 29. 12. 2022;
Pages: Str. 46-48
ID: 17688254
Recommended works:
, klinični primer
, kaj želi klinik izvedeti od radiologa
, no subtitle data available
, no subtitle data available
, klinični primer